Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies
Status:
Completed
Trial end date:
2020-08-30
Target enrollment:
Participant gender:
Summary
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a
role in the reduction of ischemic recurrences in patients with atherosclerotic disease
manifestations.
To date there is very little data, and not conducted in human subjects, on the interplay
between anti-Xa blockade with low-dose rivaroxaban and antiplatelet therapies, and in
particular how this affects profiles of platelet reactivity and thrombin generation. Given
the potential role for the use of low-dose rivaroxaban for the prevention of ischemic
recurrences in patients with atherothrombotic disease manifestations, including coronary
artery disease (CAD) and peripheral arterial disease (PAD), the study team proposes a
prospective pharmacodynamic (PD) investigation assessing the impact of low-dose rivaroxaban
when used in combination with antiplatelet treatment regimens commonly used in clinical
practice.